Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,607 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05059951Recruiting
Chemotherapy With or Without Immunotherapy for Lung Cancer
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Changsha, HunanAges 18 years+ - NCT05061550RecruitingPhase 2
Targeted immune-plus-chemo treatment before and after lung surgery
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Little Rock, ArkansasAges 18–95 - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Glendale, CaliforniaAges 18 years+ - NCT05241028RecruitingPhase 2
Adjuvant ensartinib for ALK-positive lung cancer after surgery
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
Shijiazhuang, HebeiAges 18–75 - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05284539RecruitingPhase 2
Chemo plus immunotherapy for mutated advanced lung cancer
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Changsha, HunanAges 18 years+ - NCT05341583RecruitingPhase 3
Ensartinib after lung cancer surgery for ALK-positive patients
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
TianjinAges 18 years+ - NCT05351788RecruitingPhase 2
Study drug combo for advanced lung cancer with specific gene results
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Guangzhou, GuangdongAges 18–75 - NCT05384873Recruiting
Immunonutrition to improve immunotherapy in metastatic lung cancer
This trial studies whether adding special nutrition (oral immunonutrition supplements) can help immunotherapy work better in people with metastatic non-small cell lung cancer. Participants receive immunotherapy, with or without chemotherapy, and must be able to take oral supplements.
PaviaAges 18 years+ - NCT05407168Recruiting
Conversation tool to help people make lung cancer decisions
This trial tests a low-reading-level conversation tool meant to help people with suspected lung cancer understand and make treatment decisions with their clinicians. It may help by making discussions clearer and easier to follow.
Hillsboro, OregonAges 18–99 - NCT05430009RecruitingPhase 1
Radiation to liver plus immunotherapy for metastatic lung cancer
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
Ann Arbor, MichiganAges 18 years+ - NCT05432739Recruiting
Test a lung nodule blood/scan marker to find early cancer
This study looks at whether a new test can better identify early lung cancer in people who are being watched for an incidental lung nodule. It may help doctors decide which nodules need closer follow-up or treatment.
Goodmayes, EssexAges 18 years+ - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT05445791RecruitingPhase 3
Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Mexico CityAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05486650Recruiting
Study of focused radiation after PD-1 treatment helped non-lung cancer
This observational study looks at how stereotactic (high-precision) radiation works for advanced non-small cell lung cancer that is stable after PD-1 antibody treatment (sometimes with chemotherapy). It may help doctors better understand which patients benefit from this next treatment step and what side effects to expect.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05502913RecruitingPhase 2
Fecal transplant plus cancer immunotherapy for lung cancer
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
BeershebaAges 18 years+ - NCT05522660RecruitingPhase 3
Immunotherapy or targeted therapy with focused brain radiation
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
NaplesAges 18 years+ - NCT05557552Recruiting
Chemo and immunotherapy plus chest radiation for stage III lung cancer
This trial studies a treatment plan that combines chemotherapy, immunotherapy, and radiation to the chest for people with unresectable stage III non-small-cell lung cancer (NSCLC). It may help by delivering anti-cancer drugs while also shrinking tumors with targeted radiation, especially for people who are not able to have the standard “chemo and radiation at the same time.”
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05558904RecruitingPhase 1/Phase 2
PET/CT scan to help find early lung cancer
This trial tests a special PET/CT scan to spot early lung cancer by finding specific body processes linked to cancer. It compares scan results in people with lung nodules that are either cancer (lung adenocarcinoma) or likely benign.
Los Angeles, CaliforniaAges 18 years+ - NCT05559645Recruiting
Oral drug trial for EGFR-mutated lung cancer after prior treatment
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05584267RecruitingPhase 2
Immunotherapy plus targeted brain radiation for lung cancer
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
Changsha, HunanAges 18 years+ - NCT05588388RecruitingPhase 2
Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Los Angeles, CaliforniaAges Any age
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,607 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.